Alacris Theranostics GmbH : Alacris Theranostics GmbH Announces Illumina CSPro
Certification for Next Generation Sequencing
Alacris Theranostics GmbH / Alacris Theranostics GmbH Announces Illumina CSPro
Certification for Next Generation Sequencing . Processed and transmitted by
Thomson Reuters ONE. The issuer is solely responsible for the content of this
Berlin, Germany, June 11, 2013 - Alacris Theranostics GmbH announced today
that it has successfully completed Illumina CSPro(TM) certification for next
generation sequencing (NGS); gaining entry to an elite global group of
Illumina genomics service providers. Illumina Inc., a San Diego-based company,
provides leading-edge genetic analysis tools to genomics centers worldwide.
Illumina CSPro is the collaborative service provider partnership dedicated to
ensuring the delivery of the highest-quality data available for genetic
analysis applications. Illumina CSPro participants undergo a rigorous
two-phase certification process that includes minimum data generation, data
certification, and an on-site audit of the facility and processes.
"Alacris Theranostics is advancing the field of personalised medicine by
developing new approaches for the prediction of drug treatments. To this end
the company is applying its proprietary systems biology model, ModCell(TM) for
use in drug development projects for Pharma and patient stratification in
clinical research projects. For the development of ModCell(TM) high quality
NGS data provided for example through the Illumina technology is the basis for
precise modelling predictions. Alacris also provides expertise in sequencing,
analysis and mathematical modelling within global personalised
medicine-oriented projects (for example OncoTrack (www.oncotrack.eu)).
Becoming an Illumina CSPro for NGS is valuable confirmation of Alacris
Theranostics' excellent management, laboratory and analysis standards,
important for both the company and its clients."
"Illumina CSPro recognizes organizations that provide customers with
industry-leading data quality and service in genetic analysis," said Karen
Possemato, Illumina's Sr. Director of Corporate Marketing. Now that Alacris
Theranostics is a global CSPro partner, we are excited to work with them to
make it easier for researchers in Germany to access the power of Illumina's
genetic analysis technologies."
About Alacris Theranostics
Alacris Theranostics GmbH is a Berlin-based company specialising in the
development of new personalised medicine approaches for cancer patient
diagnosis, treatment and drug stratification. Using its proprietary virtual
patient model ModCell(TM) Alacris can perform personalised prediction of drug
treatments, supporting its clients for drug development and in clinical trials
by matching patients to therapies and therapies to patients. The Alacris
Theranostics team has a strong background in academic cancer research and
collaborates closely with oncologists and pharmaceutical companies worldwide.
It also possesses extensive expertise in all aspects of NGS, from initial
experimental design through to the comprehensive analysis of sequence data,
offering this service also for a wide range of applications, including whole
genome and targeted sequencing, ChIP-Seq, RNA-Seq and microRNA/small RNA
analysis of (clinical) tumor and normal tissue samples.
Alacris Theranostics GmbH
Dr. B. Lange
Phone: +49 30 8413-1471
Fax: +49 30 8413-1465
MC Services AG
Anne Hennecke, Managing Partner
Phone: +49 89 210 228 18
Press release (PDF)
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Alacris Theranostics GmbH via Thomson Reuters ONE
--- End of Message ---
Alacris Theranostics GmbH
Fabeckstrasse 60-62 Berlin Germany
Press spacebar to pause and continue. Press esc to stop.